Literature DB >> 3566786

Membrane transport of mitoxantrone by L1210 leukemia cells.

C P Burns, B N Haugstad, J A North.   

Abstract

Transport of radiolabeled mitoxantrone, a new antineoplastic agent, was studied using cultured mouse L1210 leukemia cells. The initial velocity of influx remained linear for about 90 sec and was 110 pmoles/10(6) cells measured at 60 sec. The steady-state accumulation of about 480 pmoles/10(6) cells was not reached until 30 min. The unidirectional drug influx was linear from 0 to 1000 microM extracellular drug concentration. The initial uptake was relatively temperature independent between 37 degrees and 27 degrees, but accumulation at steady state was 17% lower at 27 degrees. None of six metabolic inhibitors had an appreciable effect on initial uptake. Efflux was initially exponential with a half-life of 2.8 min; this efflux and the residual drug concentration plateau were not affected by KCN or verapamil. Under steady-state conditions, about 86% of the cell-associated label was contained in parent drug and the remainder in an unidentified metabolite. These studies indicate that the mechanism of mitoxantrone uptake is passive diffusion. The efflux is not energy requiring, but there is considerable tight binding of the drug to cellular structures.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3566786     DOI: 10.1016/0006-2952(87)90176-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.

Authors:  J Cummings; I Meikle; J S Macpherson; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 2.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 3.  Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors:  C J Dunn; K L Goa
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

4.  Membrane lipid alteration: effect on cellular uptake of mitoxantrone.

Authors:  C P Burns; B N Haugstad; C J Mossman; J A North; L M Ingraham
Journal:  Lipids       Date:  1988-05       Impact factor: 1.880

5.  Inhibition of DNA Topoisomerase Type IIα (TOP2A) by Mitoxantrone and Its Halogenated Derivatives: A Combined Density Functional and Molecular Docking Study.

Authors:  Md Abu Saleh; Md Solayman; Mohammad Mazharol Hoque; Mohammad A K Khan; Mohammed G Sarwar; Mohammad A Halim
Journal:  Biomed Res Int       Date:  2016-02-15       Impact factor: 3.411

6.  Surface PEGylation of Mesoporous Silica Nanorods (MSNR): Effect on loading, release, and delivery of mitoxantrone in hypoxic cancer cells.

Authors:  Amit Wani; Galbokka H Layan Savithra; Ayat Abyad; Shrey Kanvinde; Jing Li; Stephanie Brock; David Oupický
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

7.  Cytotoxicity of weak electrolytes after the adaptation of cells to low pH: role of the transmembrane pH gradient.

Authors:  S V Kozin; L E Gerweck
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.